---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-076613"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:18:00.647956+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sangamo Therapeutics announces $24M registered direct offering of common stock and warrants

## Summary
- Offering includes 24.8M shares, 3.8M pre-funded warrants, and 28.6M purchase warrants at $0.84/unit.
- Gross proceeds expected ~$24.0M; closing on or about March 26, 2024.
- Placement agents: Barclays Capital Inc. and Cantor Fitzgerald & Co.; 6% cash fee.
- Pre-funded warrant exercise price $0.01; purchase warrant exercise price $1.00 with 5.5-year term.
- Lock-Up Agreements from directors and officers restrict share sales for a period.

## SEC filing metadata
- accession: 0001193125-24-076613
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/0001193125-24-076613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/d816036d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-076613
- JSON: https://secwatch.observer/filing/0001193125-24-076613.json
- Plain text: https://secwatch.observer/filing/0001193125-24-076613.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.